Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Maria Colia"'
Autor:
Lydia Scarfò, Silvia Heltai, Elisa Albi, Eloise Scarano, Luana Schiattone, Lucia Farina, Riccardo Moia, Marina Deodato, Andrea Ferrario, Marina Motta, Alessandro Noto, Rosaria Sancetta, Marta Coscia, Paolo Rivela, Luca Laurenti, Marzia Varettoni, Eleonora Perotta, Antonella Capasso, Pamela Ranghetti, Francesca Martini, Emanuela Sant’antonio, Catalina Combi, Maria Colia, Paolo Ghia
Publikováno v:
HemaSphere, Vol 7, p e8082529 (2023)
Externí odkaz:
https://doaj.org/article/ee82130cdd2c4c59b242b7ec6877076b
Autor:
Alessandro Campanella, Antonella Capasso, Caterina Taccetti, Silvia Heltai, Elisa Albi, Yair Herishanu, Sabine Haggenburg, Thomas Chatzikonstantinou, Michael Doubek, Magdalena Kättström, Krzysztof Giannopoulos, Martin Simkovic, Carol Moreno, Massimo Massaia, Horia Bumbea, Salem Al Shimmari, Pamela Ranghetti, Eleonora Perotta, Francesca Martini, Emanuela Sant’antonio, Maria Colia, Catalina Combi, Shai Levi, Arnon Kater, Mette Hazenberg, Inger Nijhof, Quincy Hofsink, Christos Demosthenous, Jana Kotaskova, Joanna Zaleska, Filip Vrbacky, Alba Mora, Davide Bisogno, Ignazio Ezio Tripoli, Viola Maria Popov, Viviana Roman, Eloise Scarano, Michela Frenquelli, Lydia Scarfò, Kostas Stamatopoulos, Paolo Ghia
Publikováno v:
HemaSphere, Vol 7, p e483427a (2023)
Externí odkaz:
https://doaj.org/article/95dec98f89594135be22f30c2711ec0e
Autor:
Antonella Capasso, Elisa Albi, Luana Schiattone, Francesca Martini, Emanuela Sant'Antonio, Lydia Scarfò, Pamela Ranghetti, Michela Frenquelli, Alessandro Campanella, Eleonora Perotta, Silvia Heltai, Maria Colia, Paolo Ghia
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:S279-S280
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ce95b26129e7b399c2b92e1ae3077266
https://doi.org/10.1016/s2152-2650(22)01348-9
https://doi.org/10.1016/s2152-2650(22)01348-9
Autor:
Lydia Scarfò, Silvia Ferrari, Anna Maria Frustaci, Monica Tani, Alessia Bari, Eloise Scarano, Maria Colia, Pamela Ranghetti, Piera Angelillo, Paola Ronchi, Maurilio Ponzoni, Andrés J. M. Ferreri, Paolo Ghia
Publikováno v:
Blood advances. 6(18)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce74b25e59816484dd24ce54c7d961cf
https://pubmed.ncbi.nlm.nih.gov/35613463
https://pubmed.ncbi.nlm.nih.gov/35613463
Autor:
Lydia Scarfò, Silvia Heltai, Elisa Albi, Eloise Scarano, Luana Schiattone, Lucia Farina, Riccardo Moia, Marina Deodato, Andrea Ferrario, Marina Motta, Gianluigi Reda, Rosaria Sancetta, Marta Coscia, Paolo Rivela, Luca Laurenti, Marzia Varettoni, Eleonora Perotta, Antonella Capasso, Pamela Ranghetti, Maria Colia, Paolo Ghia
Undetectable measurable residual disease (uMRD) is achievable in patients with chronic lymphocytic leukemia (CLL) with the BCL2-inhibitor venetoclax alone or combined with the Bruton’s tyrosine kinase inhibitor ibrutinib. This phase 2, multicenter,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38d77801a7db73233231e979e5426ed6
https://hdl.handle.net/10807/235634
https://hdl.handle.net/10807/235634
Autor:
Antonella Capasso, Elisa Albi, Luana Schiattone, Francesca Martini, Emanuela Sant'Antonio, Lydia Scarfò, Pamela Ranghetti, Michela Frenquelli, Alessandro Campanella, Eleonora Perotta, Silvia Heltai, Maria Colia, Paolo Ghia
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:S143
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6b10b6e0eeac5a11d43c43c53e52671a
https://doi.org/10.1016/s2152-2650(22)00869-2
https://doi.org/10.1016/s2152-2650(22)00869-2
Autor:
Pamela Ranghetti, Elisa Albi, Maria Colia, Eloise Scarano, Paolo Ghia, Andrea Ferrario, Marco Ladetto, Antonella Capasso, Silvia Heltai, Luana Schiattone, Rosaria Sancetta, Luca Laurenti, Marzia Varettoni, Lydia Scarfò, Marina Deodato, Eleonora Perotta, Gianluca Gaidano, Gianluigi Reda, Marina Motta, Marta Coscia, Lucia Farina
Publikováno v:
Blood. 136:21-22
The treatment of chronic lymphocytic leukemia (CLL) has been radically changed in the last years thanks to the targeted therapies, including kinase (i.e. ibrutinib) and BCL2 (i.e. venetoclax) inhibitors. Venetoclax (VEN) in particular is able to obta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5bb91cf9dcd06bac1730d8ed7ccbf476
https://doi.org/10.1182/blood-2020-136507
https://doi.org/10.1182/blood-2020-136507